Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.

ABSTRACT: The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or 2019 novel coronavirus (2019-nCoV), took tens of thousands of lives and caused tremendous economic losses. The main protease (M^pro) of SARS-CoV-2 is a potential target for treatment of COVID-19 due to its critical role in maturation of viral proteins and subsequent viral replication. Conceptually and technically, targeting therapy against M^pro is similar to target therapy to treat cancer. Previous studies show that GC376, a broad-spectrum dipeptidyl M^pro inhibitor, efficiently blocks the proliferation of many animal and human coronaviruses including SARS-CoV, Middle East respiratory syndrome coronavirus (MERS-CoV), porcine epidemic dia

SUBMITTER: Wang YC 

PROVIDER: S-EPMC7471349 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature